

## VALBIOTIS received two public subventions for a total amount of 885 000 euros

**La Rochelle, 2<sup>nd</sup> April 2019** (5:40 CEST) – **VALBIOTIS** (FR0013254851 - ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, **today announced the obtention of two public subventions: a € 536,866 subvention granted by the Nouvelle-Aquitaine Region and a € 350,000 subvention granted by the Auvergne-Rhône-Alpes Region, including a government contribution within the investment program “Programme d’Investissements d’Avenir”.**

These two non-dilutive public fundings, for a total amount of € 886,866, will contribute to support the fast growing Marketing and Business Development activities for VALEDIA®, and the R&D efforts on this innovative product, designed to help prediabetics to reduce their risk of type 2 diabetes.



**Jocelyn PINEAU**  
Chief Financial Officer of VALBIOTIS

“ This important public funding is very encouraging and confirms the recognition of our project by the public authorities. They support our strategy, with a clear priority: the launch of VALEDIA® by 2021. Beyond this, we thank our two regional partners, the Nouvelle-Aquitaine and Auvergne-Rhône-Alpes, for their strong commitment that witnesses our development in these two regions since the creation of the Company in 2014”, comments Jocelyn PINEAU, Chief Financial Officer of VALBIOTIS.

The subvention of Euros 536,866 granted by the Nouvelle-Aquitaine region relates specifically to the Marketing and Business Development activities, which have grown since 2019, aiming at a licensing agreement for VALEDIA® with a health player.

The € 350,000 subvention from the Auvergne-Rhône-Alpes region, which includes a State funding, will contribute to the continuation of the R&D effort on VALEDIA®, carried out mostly on the platform in Riom (Puy-de-Dôme).

VALBIOTIS is located on three sites in France, in these two regions:

- **In Nouvelle-Aquitaine:** headquarters and clinical research center (Périgny, Charente-Maritime), plant chemistry center (La Rochelle, Charente-Maritime),
- **In Auvergne-Rhône-Alpes:** platform for Discovery and Preclinical and Translational Research (Riom, Puy-de-Dôme).

Since its creation, VALBIOTIS has the support of local authorities and public structures such as Bpifrance or the European Regional Development Fund (ERDF).

## ABOUT VALBIOTIS

VALBIOTIS is a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the healthcare sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The company is located at 3 sites in France - Périgny, La Rochelle (17) and Riom (63) - in addition to an american office in Boston (MA).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

VALBIOTIS is PEA/SME eligible.

Find out more about VALBIOTIS:

[www.valbiotis.com](http://www.valbiotis.com)



Name: VALBIOTIS - ISIN Code: FR0013254851 - Mnemonic code: ALVAL



**C O N T A C T S**

**FRANCE.**  
**CORPORATE COMMUNICATION | VALBIOTIS**  
Carole ROCHER / Marc DELAUNAY  
+33 5 46 28 62 58 | [carole.rocher@valbiotis.com](mailto:carole.rocher@valbiotis.com) / [marc.delaunay@valbiotis.com](mailto:marc.delaunay@valbiotis.com)

**FINANCIAL COMMUNICATION | ACTIFIN**  
Stéphane RUIZ  
+33 1 56 88 11 14 | [sruiz@actifin.fr](mailto:sruiz@actifin.fr)

**MEDIA RELATIONS | MADIS PHILEO**  
Guillaume DE CHAMISSO  
+ 33 6 85 91 32 56 | [guillaume.dechamisso@madisphileo.com](mailto:guillaume.dechamisso@madisphileo.com)

**UNITED STATES.**  
**SOLEBURY TROUT**  
Rebecca JOHN / Patrick TILL  
+1.646.378.2935 | [rjohn@troutgroup.com](mailto:rjohn@troutgroup.com) / [ptill@troutgroup.com](mailto:ptill@troutgroup.com)

## Disclaimer

This press release contains forward-looking statements concerning the objectives of VALBIOTIS. VALBIOTIS considers that these projections are based on information currently available by VALBIOTIS and on reasonable assumptions.

However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of VALBIOTIS filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number I.17-012 on April 5, 2017 as well as in its 2018 annual financial report filed with the French Financial Markets Authority on March 8, 2019. These documents are available on the Company's website ([www.valbiotis.com](http://www.valbiotis.com)).

VALBIOTIS declines all responsibility for updating or revising these forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, VALBIOTIS shares in any country.

